about
A new look at an old virus: patterns of mutation accumulation in the human H1N1 influenza virus since 1918Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3)Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsCurrent perspectives on HIV-1 antiretroviral drug resistanceRibavirin Reveals a Lethal Threshold of Allowable Mutation Frequency for Hantaan VirusStructural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic InstabilityMutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461Stochastic simulations suggest that HIV-1 survives close to its error thresholdLethal mutagenesis of bacteriaLeveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidineExamining the theory of error catastrophe.Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.Lethal mutagenesis: targeting the mutator phenotype in cancer.Phylogenetic and recombination analysis of Tobacco bushy top virus in ChinaRecombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant formRunning loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif proteinEmergence of DNA polymerase ε antimutators that escape error-induced extinction in yeast.The remarkable frequency of human immunodeficiency virus type 1 genetic recombinationComparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations."Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.Concomitant lethal mutagenesis of human immunodeficiency virus type 1.HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Interrelationship between HIV-1 fitness and mutation rate.Error catastrophe and phase transition in the empirical fitness landscape of HIV.Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine.Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli.Activity-based selection of HIV-1 reverse transcriptase variants with decreased polymerization fidelity.Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
P2860
Q21245216-D5BC1D1F-B307-4E54-AD60-9970DF4C0AE0Q24645606-0CA61E50-6816-4F19-8A7B-8B0035DA8B61Q26777448-2A38BED2-2510-4311-8CBD-370B71BF7E8DQ26852626-03EBB5F7-CF24-44C4-9169-78DA8FECD3ACQ27484998-D05C5A74-84C2-4EF6-A15D-B0C98D349C37Q28074527-73C55BED-7CD4-4EFA-96E8-5F8D6D67B316Q28476736-53CC2F64-F2A4-4CC2-8314-5419BE23B103Q28483749-F8A41854-366F-4881-A885-92746E166435Q28756839-CA1C49E0-BBA3-4EFA-BD03-450F453C054FQ33654949-7CA29D5F-4C8F-4131-A85E-4E4A29471023Q34060532-4CC4AAC9-4AD6-4B51-BFB4-FD6605D3597DQ34232954-777BD22A-D511-4F06-957A-819884D19359Q34249277-09C125E3-2CF6-4A46-8CBC-A77D19701DD9Q34412763-9185B189-3E68-4DEA-A6A8-8993CF80B632Q35000909-6A13C786-93B3-4ABF-A04C-5ABCDE1C3A0AQ35669158-D92DA827-20EA-4869-992A-E83D3700F7DCQ35713180-143F22EC-AD2D-4A8B-9A6F-5CC3BF22EE99Q35947721-51661B58-9A67-4D8E-AC0B-CB0B65D4E7B2Q36432758-9FA3EB2A-15F8-4210-A252-0C646912BADDQ36643853-A1B2F383-DA52-42D6-9381-F945BA04F88EQ37333701-686E7015-0FA9-466E-91AB-9194018B9206Q37630336-6FF5FC6D-4488-45A5-95C3-40C310D8A31DQ38212854-F66ECCF0-D5EC-4022-A930-71DBF83839DDQ38543385-4FC45F1D-1EEE-47E3-AB97-1E24B630C2D8Q39080441-7C119E01-35D0-4116-9021-EB86CB99FEFAQ39378134-9E97467D-5D8C-4A6A-8849-38395657EF7EQ39835202-0D0B0D5E-B1A5-41DA-A8F0-9AA16DD409CFQ41879018-70DB8FEA-0045-4762-A90F-BCEFF9F5E9D1Q41888126-8B071B50-B3CA-4771-AAAF-24F31D7760C5Q42148868-70512114-935F-4C20-ADFD-3B96884D288EQ42400705-BCCA20DD-9E51-4100-92A7-4A0E1D56A1D9Q42705384-73D6E69A-4601-4352-96FD-C77F8DAA9E75Q54682786-6AEEE60F-4B13-458E-9BA8-B87E0A906BD8Q55154648-9D2EB331-840D-4E37-802A-289D1DE52353
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Lethal mutagenesis of HIV.
@ast
Lethal mutagenesis of HIV.
@en
type
label
Lethal mutagenesis of HIV.
@ast
Lethal mutagenesis of HIV.
@en
prefLabel
Lethal mutagenesis of HIV.
@ast
Lethal mutagenesis of HIV.
@en
P2093
P1433
P1476
Lethal mutagenesis of HIV.
@en
P2093
Bradley D Preston
Lawrence A Loeb
Robert A Smith
P304
P356
10.1016/J.VIRUSRES.2004.11.011
P577
2005-02-01T00:00:00Z